Yüksel Ürün, Medical Oncology professor at Ankara University School of Medicine, shared a post on X:
“HER2 testing is evolving.
Current IHC = poor sensitivity and discordance
New tools: QIF, RNA, AI, digital scoring
Needed for HER2-low and -ultralow ADC decisions.”
HER2 testing: evolution and update for a companion diagnostic assay
Authors: Charles J. Robbins, Katherine M. Bates, David L. Rimm
